eISSN: 1897-4317
ISSN: 1895-5770
Gastroenterology Review/Przegląd Gastroenterologiczny
Bieżący numer Archiwum Artykuły zaakceptowane O czasopiśmie Rada naukowa Bazy indeksacyjne Prenumerata Kontakt Zasady publikacji prac
NOWOŚĆ
Portal dla gastroenterologów!
www.egastroenterologia.pl
SCImago Journal & Country Rank
Poleć ten artykuł:
Udostępnij:
więcej
 
 
Artykuł przeglądowy

Markers of metastatic colorectal cancer

Piotr Myśliwiec
,
Barbara Choromanska
,
Jacek Dadan

Data publikacji online: 2019/05/08
Plik artykułu:
Pobierz cytowanie
ENW
EndNote
BIB
JabRef, Mendeley
RIS
Papers, Reference Manager, RefWorks, Zotero
AMA
APA
Chicago
Harvard
MLA
Vancouver
 
 

Introduction

Metastatic colorectal cancer (CRC) is a major cause of cancer-related death [1–4]. Resection of limited metastases offers 10-year survival in up to 38% of patients [5]. Moreover, recent development of minimally invasive techniques has reduced the morbidity and improved the cost-effectiveness of liver surgery, similarly to other types of procedures [6, 7]. Thus, early detection of metastatic CRC is of utmost importance for patients who are candidates for surgery [5]. Current guidelines recommend intensive surveillance for the first 5 years after curative treatment of stage II and III CRC. They are based on clinical examination, carcinoembryonic antigen (CEA) testing, computed tomography (CT) scanning, and endoscopic surveillance [1, 2]. Intensive follow-up (every 3–6 months for the first years after primary CRC operation) was shown to be on average three times better in diagnosing resectable CRC metastases than minimum follow-up based on symptoms [8]. Because laboratory tests seem more convenient and objective than clinical examination and carry less risk than CT scanning or endoscopy, in this paper we concentrate on laboratory markers of CRC. Most of them are not useful in differentiation between local recurrence and distant metastases. Hence in this study we focus on markers with the strongest association with metastatic CRC, especially useful in surveillance after surgical treatment. All the markers presented in the study have the potential to detect synchronous or metachronous metastases.

Proteins

Most professional guidelines on surveillance after resected colon and rectal cancer include CEA testing every 3–12 months for the first 3–5 years [1, 2]. This is based on initial studies showing that an increase in CEA levels often precedes the diagnosis using other methods. However, CEA was shown to have very low sensitivity (Table I). Shinkins et al. [9] demonstrated that with the threshold of 5 µg/l CEA testing achieves at best 50% of detected CRC recurrences. At the same time, false alarms would be present in 56.7% of patients, reflecting the low specificity of CEA assessment. Lowering the CEA threshold to 2.5 µg/l would reduce the percentage of missed recurrences to 36.5 at the cost of 84.2% of false alarms. The authors concluded that not the single result, but the trend of consecutive CEA measurements should be the basis of clinical decision making [10]. Intensive CEA monitoring has the potential to select a group of patients who could benefit from recurrence treatment [10]. Notwithstanding, this strategy has not been proven to result in survival benefit [11].
6-integrin has been recently reported as a novel promising serum marker of CRC. A cut-off value of ≥ 2 ng/ml had 100% specificity for metastatic CRC (Table I). In a study cohort of 269 CRC patients, 6-integrin predicted the onset of metastatic disease. In the same study, the results were prospectively confirmed in 40 CRC patients [12]. CA 11-19 is a glycoprotein marker of early CRC and adenomatous polyps (Table I). Data about association between CA 11-19 and metastatic CRC is lacking [13].
Dendritic cell-specific intercellular adhesion molecule-3-grabbing non-integrin (DC-SIGN), also known as CD209 (cluster of differentiation 209), belongs to the group of lectins, found on the surface of dendritic cells. DC-SIGN can initiate recognition of tumour cells. Decreased serum DC-SIGN was associated with stage I/II colon cancer and short survival. Notwithstanding, DC-SIGN does not seem to be a marker of metastatic CRC [13, 14]. Dendritic cell-specific intercellular adhesion molecule-3-grabbing non-integrin-related protein DC-(SIGNR) is an analogue of DC-SIGN found on endothelial cells in the liver and lymph nodes [15]. In contrast to DC-SIGN, DC-SIGNR has been reported to increase in stage I/II CRC [13, 14]. It has been demonstrated in a mouse model that DC-SIGNR plays a role in hepatic metastasis of CRC. Knocking down DC-SIGNR decreased the liver metastatic potency of CRC and increased survival, while expressing DC-SIGNR enhanced CRC liver metastases. Moreover, in the same paper the authors revealed that patients with metastatic CRC had greater serum DC-SIGNR concentrations than those without metastases (Table I) [15].

Carbohydrates

Carbohydrate antigen 19-9 (CA 19-9) has low sensitivity (Table I). Admittedly, a strong correlation has been reported between CA 19-9 and nodal involvement of CRC, but not with metastases to liver or lungs [13, 16].

Nucleic acids

At present, tissue sampling remains the gold standard in the assessment of tumour genetic features [17]. A fraction of CRC DNA is shed into the blood, and sensitive methods to detect it have now been introduced. Assessment of circulating tumour DNA (ctDNA) has the potential to not only detect CRC recurrence, but also to identify its genetic or epigenetic features. Information about RAS or BRAF mutation, HER2 amplification, or microsatellite instability are especially valuable in order to tailor target treatment of metastatic CRC. With the advent of modern methods allowing the use of plasma for genetic testing, the term “liquid biopsy” was introduced. Quick and less invasive, it also avoids the bias of tissue sampling, associated with the difficulty of obtaining sufficient material of good quality using fine needle aspiration [18]. A study on 27 patients treated for CRC revealed that all 14 subjects with elevated ctDNA had tumour relapse, whereas among 13 remaining patients with normal ctDNA no relapse was found [19]. Another prospective study on 45 patients with CRC showed significant association of detectable ctDNA with inferior relapse-free survival during 2 years of follow-up. The authors recommended ctDNA testing upon equivocal results of standard investigations [20]. Moreover, a strong correlation between ctDNA and liver metastases has been reported (Table I) [18].
Despite its potential utility for early diagnosis of metastatic CRC, ctDNA testing is associated with some disadvantages: limited evidence for treatment selection in advanced cancer and incomplete correlation with cellular phenotype or histology. To increase the sensitivity and specificity of ctDNA assessment, tests to detect multiple mutations during one study have been introduced [18]. So far, ctDNA assessment has not been validated for surveillance of patients with CRC. However, dynamic development in methodology and extensive studies might establish the role of ctDNA in this domain.
Another method of DNA assessment in blood is cell free DNA (cfDNA), the total concentration of DNA in serum. However, the association of cfDNA with CRC metastases is much weaker than for ctDNA [18]. The best studied marker in recent years was SEPT9 methylated DNA. Its sensitivity showed great variability (48.2–95.6%) and specificity (80–98.9%) (Table I). Until it becomes more repetitive, the clinical utility of SEPT9 methylated DNA remains doubtful. Other promising nucleic acid-based tests are the following: NEAT-v2 non-coding RNA, DC-SIGN/DC-SIGNR, SDC2 methylated DNA, ALU115 of circulating free DNA, mi-155, and mi1290. However, until they are studied in multicentre prospective trials, no clinical conclusions can be drawn [13].
Genetic information about CRC can also be obtained from microRNA (miRNA) analysis. miRNAs are stable, small, non-coding sequences of RNA, responsible for post-transcriptional control of gene expression and important for CRC proliferation, invasion, and metastasis formation [18, 21, 22]. However, microRNA testing has low to moderate (for mi-1290 and mi-155) power to discriminate metastatic advanced from early CRC (Table I) [13].

Cytokines

Growth/differentiation factor 15 (GDF-15) is a macrophage inhibitory cytokine (MIC-1) belonging to the transforming growth factor- superfamily. GDF-15 testing sensitivity is low and comparable to CEA (Table I). However, in contrast to CEA, GDF-15 has been reported to correlate strongly with the extent of liver metastases of CRC, so it may be of use if/when confirmed in further studies [13].
Interleukin-8 is a chemokine, involved in the proliferation, angiogenesis, and migration of cancer cells. Interleukin-8 testing in patients with CRC has high specificity and sensitivity; however, its clinical utility remains to be established (Table I) [13].
Many other substances important for cancer and metastasis have been studied, such as interleukin-6, with no evidence of added benefit to the current guidelines [23, 24].

Perspectives

The invasiveness of a testing tool is an important factor influencing patients’ adherence to guidelines. Saliva has been suggested as preferable to blood in terms of technical simplicity and potential diagnostic usefulness, demonstrated for assessment of miRNA: miR-21 [22, 25]. Preliminary urinary tests have also been performed, showing urinary ctDNA to be 90% concordant with tissue testing [26]. This compares favourably to blood testing and may open a new perspective in studies on CRC markers.
The metastatic potential of CRC is regulated by mechanisms involving several types of signalling, influencing cancer cell mobility, invasiveness, angiogenesis, intercellular adhesion, and lipid metabolism [27–30]. The search for novel metastatic CRC markers is being continued.

Conclusions

Tumour markers are an important element of intensive surveillance in patients after resection of early CRC. CEA remains the best documented diagnostic tool suggesting CRC recurrence; however, it has low sensitivity and specificity. To increase the value of CEA testing, a trend of consecutive measurements should be analysed rather than a single absolute concentration. Among novel markers, the strongest association with CRC metastases was reported for ctDNA, GDF15, and 6-integrin. Further prospective multicentre studies are needed to validate and define the clinical utility of metastatic CRC.

Conflict of interest

The authors declare no conflict of interest.

References

1. Meyerhardt JA, Mangu PB, Flynn PJ, et al. Follow-up care, surveillance protocol, and secondary prevention measures for survivors of colorectal cancer: American Society of Clinical Oncology clinical practice guideline endorsement. J Clin Oncol 2013; 31: 4465-70.
2. Glynne-Jones R, Wyrwicz L, Tiret E, et al. Rectal cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 2017; 28 (Suppl 4): iv22.
3. Emre A, Akbulut S, Sertkaya M, et al. Assessment of risk factors affecting mortality in patients with colorectal cancer. Gastroenterology Rev 2018; 13: 109-17.
4. Lamami Y, Mesediyeva R, Arikan S, et al. Preliminary report: one of the PD-1 gene variants may be a valuable marker for colorectal cancer. Arch Med Sci Civil Dis 2018; 3: e34-40.
5. Zizzo M, Galeone C, Braglia L, et al. Long-term outcomes after surgical resection for synchronous or metachronous hepatic and pulmonary colorectal cancer metastases. Digestion 2019 Feb 15: 1-12.
6. Fretland ÅA, Dagenborg VJ, Bjørnelv GMW, et al. laparoscopic versus open resection for colorectal liver metastases: the OSLO-COMET randomized controlled trial. Ann Surg 2018; 267: 199-207.
7. Mysliwiec P, Marek-Safiejko M, Lukaszewicz J, et al. Videoscopic adrenalectomy – when does retroperitoneal seem better? Videosurgery Miniinv 2014; 9: 226-33.
8. Primrose JN, Perera R, Gray A, et al. Effect of 3 to 5 years of scheduled CEA and CT follow-up to detect recurrence of colorectal cancer: the FACS randomized clinical trial. JAMA 2014; 311: 263-70.
9. Shinkins B, Nicholson BD, Primrose J, et al. The diagnostic accuracy of a single CEA blood test in detecting colorectal cancer recurrence: results from the FACS trial. PLoS One 2017; 12: e0171810.
10. Bruinvels DJ, Stiggelbout AM, Kievit J, et al. Follow-up of patients with colorectal cancer. A meta-analysis. Ann Surg 1994; 219: 174-82.
11. Treasure T, Monson K, Fiorentino F, et al. The CEA Second-Look Trial: a randomised controlled trial of carcinoembryonic antigen prompted reoperation for recurrent colorectal cancer. BMJ Open 2014; 4: e004385.
12. Bengs S, Becker E, Busenhart P, et al. beta6-integrin serves as a novel serum tumor marker for colorectal carcinoma. Int J Cancer 2019 Jan 17. doi: 10.1002/ijc.32137.
13. Nikolaou S, Qiu S, Fiorentino F, et al. Systematic review of blood diagnostic markers in colorectal cancer. Tech Coloproctol 2018; 22: 481-98.
14. Jiang Y, Zhang C, Chen K, et al. The clinical significance of DC-SIGN and DC-SIGNR, which are novel markers expressed in human colon cancer. PLoS One 2014; 9: e114748.
15. Na H, Liu X, Li X, et al. Novel roles of DC-SIGNR in colon cancer cell adhesion, migration, invasion, and liver metastasis. Hematol Oncol 2017; 10: 28.
16. Yu Z, Chen Z, Wu J, et al. Prognostic value of pretreatment serum carbohydrate antigen 19-9 level in patients with colorectal cancer: a meta-analysis. PLoS One 2017; 12: e0188139.
17. Kuklinski A, Kamocki Z, Koda M, et al. IGF-IR in patients with advanced colorectal cancer in correlation with certain clinico-morphological factors: Initial report. Oncol Lett 2011; 2: 1155-9.
18. Osumi H, Shinozaki E, Takeda Y, et al. Clinical relevance of circulating tumor DNA assessed through deep sequencing in patients with metastatic colorectal cancer. Cancer Med 2019; 8: 408-17.
19. Schøler LV, Reinert T, Ørntoft MW, et al. Clinical implications of monitoring circulating tumor DNA in patients with colorectal cancer. Clin Cancer Res 2017; 23: 5437-45.
20. Wong R, Tie J, Lee M, et al. The potential role of circulating tumor DNA (ctDNA) in the further investigation of colorectal cancer patients with nonspecific findings on standard investigations. Int J Cancer 2019 Jan 10. doi: 10.1002/ijc.32117.
21. Vacante M, Borzì AM, Basile F, et al. Biomarkers in colorectal cancer: current clinical utility and future perspectives. World J Clin Cases 2018; 6: 869-81.
22. Sazanov AA, Kiselyova EV, Zakharenko AA, et al. Plasma and saliva miR-21 expression in colorectal cancer patients. J Appl Genet 2017; 58: 231-7.
23. Zeng J, Tang ZH, Liu S, et al. Clinicopathological significance of overexpression of interleukin-6 in colorectal cancer. World J Gastroenterol 2017; 23: 1780-6.
24. Mysliwiec J, Zbucki R, Winnicka MM, et al. A crucial role of interleukin-6 in the pathogenesis of thyrotoxicosis-related disturbances of bone turnover in mice. Horm Metab Res 2007; 39: 884-8.
25. Choromanska K, Choromanska B, Dabrowska E, et al. Saliva of obese patients – is it different? Postepy Hig Med Dosw 2015; 69: 1190-5.
26. Song T, Mao F, Shi L, et al. Urinary measurement of circulating tumor DNA for treatment monitoring and prognosis of metastatic colorectal cancer patients. Clin Chem Lab Med 2018; 57: 268-75.
27. Kawaguchi K, Senga S, Kubota C, et al. High expression of fatty acid-binding protein 5 promotes cell growth and metastatic potential of colorectal cancer cells. FEBS Open Bio 2016; 6: 190-9.
28. Choromanska B, Mysliwiec P, Dadan J, et al. The clinical significance of fatty acid binding proteins. Postepy Hig Med Dosw 2011; 65: 759-63.
29. Mysliwiec H, Baran A, Harasim-Symbor E, et al. Increase in circulating sphingosine-1-phosphate and decrease in ceramide levels in psoriatic patients. Arch Dermatol Res 2017; 309: 79-86.
30. Jafari N, Drury J, Morris AJ, et al. De novo fatty acid synthesis-driven sphingolipid metabolism promotes metastatic potential of colorectal cancer. Mol Cancer Res 2019; 17: 140-52.
Copyright: © 2019 Termedia Sp. z o. o. This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) License (http://creativecommons.org/licenses/by-nc-sa/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
© 2019 Termedia Sp. z o.o. All rights reserved.
Developed by Bentus.
PayU - płatności internetowe